Disclosures for "From Brain to Bone Marrow: Concurrent Use of Bruton’s Tyrosine Kinase Inhibition and Anti-CD20 Therapy in Relapsing Multiple Sclerosis With Chronic Lymphocytic Leukemia"
-
Ms. Patel has nothing to disclose.
-
Dr. Maynard has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics. Dr. Maynard has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Maynard has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for EMD Serono.
-
Dr. Gautam has stock in IBRX. Dr. Gautam has stock in CRDF. An immediate family member of Dr. Gautam has stock in CRSP. Dr. Gautam has stock in PFE. Dr. Gautam has stock in RCUS.
-
Dr. Hooshmand has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genetech USA. Dr. Hooshmand has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for TG Therapeutics . Dr. Hooshmand has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amgen. Dr. Hooshmand has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genetech USA. Dr. Hooshmand has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for EMD Serono. Dr. Hooshmand has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for TG Therapeutics . Dr. Hooshmand has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Amgen . The institution of Dr. Hooshmand has received research support from Novartis .